Skip to main content

Advertisement

Table 2 Ongoing phase 3 trials on anti-amyloid therapy in AD in 2019

From: Clinical trials of new drugs for Alzheimer disease

AgentMechanism of actionTarget type and therapeutic purposeClinicalTrials.gov identifierStatus 
Plasma exchange with albumin 1 immunoglobulinPlasma exchangeRemove amyloidNCT01561053Completed 
ALZT-OP1a + ALZT-OP1bMast cell stabilizer, anti-inflammatoryAmyloid-related and antineuroinflammatoryNCT02547818Active, not recruiting 
ANAVEX2–73Anti-tau, Anti-amyloidAnti-tau, anti-amyloid, and antineuroinflammatoryNCT03790709Recruiting 
CrenezumabMonoclonal antibody directed at oligomersRemove amyloidNCT02670083.NCT03114657.NCT03491150Completed 
E2609 (elenbecestat)BACE inhibitorReduce amyloid productionNCT02956486.NCT03036280Active, not recruiting 
GantenerumabMonoclonal antibodyRemove amyloidNCT02051608.NCT01224106.NCT03444870.NCT03443973NCT02051608.NCT01224106 Active, not recruiting, NCT03444870.NCT03443973 Recruiting 
Gantenerumab and SolanezumabMonoclonal antibodyRemove amyloid/reduce amyloid productionNCT01760005Recruiting 
GV-971 (sodium oligomannurarate)Aβ aggregation inhibitorAmyloid-relatedNCT02293915Completed 
SolanezumabMonoclonal antibodyRemove amyloid and prevent
aggregation
NCT02008357Active, not recruiting